{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(15)"],"submitter":["Hammer S"],"funding":["Bayer AG"],"pubmed_abstract":["<h4>Purpose</h4>Androgen receptor (AR) inhibitors are well established in the treatment of castration-resistant prostate cancer and have recently shown efficacy also in castration-sensitive prostate cancer. Although most patients respond well to initial therapy, resistance eventually develops, and thus, more effective therapeutic approaches are needed. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and presents an attractive target for radionuclide therapy. Here, we evaluated the efficacy and explored the mode of action of the PSMA-targeted thorium-227 conjugate (PSMA-TTC) BAY 2315497, an antibody-based targeted alpha-therapy, in combination with the AR inhibitor darolutamide.<h4>Experimental design</h4>The <i>in vitro</i> and <i>in vivo</i> antitumor effi"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["4367-4378"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401501"],"repository":["biostudies-literature"],"pubmed_title":["Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models."],"pmcid":["PMC9401501"],"pubmed_authors":["Schlicker A","Schatz CA","Nielsen CH","Mumberg D","Karlsson J","Ellingsen C","Zitzmann-Kolbe S","Juul MU","Hagemann UB","Lejeune P","Scholz A","Hammer S","Haendler B","Hennekes H","Baumgart S"],"additional_accession":[]},"is_claimable":false,"name":"Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models.","description":"<h4>Purpose</h4>Androgen receptor (AR) inhibitors are well established in the treatment of castration-resistant prostate cancer and have recently shown efficacy also in castration-sensitive prostate cancer. Although most patients respond well to initial therapy, resistance eventually develops, and thus, more effective therapeutic approaches are needed. Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and presents an attractive target for radionuclide therapy. Here, we evaluated the efficacy and explored the mode of action of the PSMA-targeted thorium-227 conjugate (PSMA-TTC) BAY 2315497, an antibody-based targeted alpha-therapy, in combination with the AR inhibitor darolutamide.<h4>Experimental design</h4>The <i>in vitro</i> and <i>in vivo</i> antitumor effi","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2026-06-14T07:45:07.919Z","creation":"2025-04-04T13:08:57.888Z"},"accession":"S-EPMC9401501","cross_references":{"pubmed":["34035067"],"doi":["10.1158/1078-0432.CCR-21-0342"]}}